{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Trevi Therapeutics, Inc. technically bullish or bearish?
As of May 13, 2025, the trend is mildly bullish with daily moving averages supporting this view, but mixed signals from weekly indicators suggest caution due to potential short-term volatility.
Who are in the management team of Trevi Therapeutics, Inc.?
As of March 2022, the management team of Trevi Therapeutics, Inc. includes Dr. David Meeker (Independent Chairman), Ms. Jennifer Good (President, CEO, Co-Founder, Director), and Directors Mr. Dominick Colangelo, Mr. Edward Mathers, Dr. James Cassella, and Mr. Michael Heffernan.
What does Trevi Therapeutics, Inc. do?
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing nalbuphine ER for neurologically mediated conditions. As of March 2025, it has a market cap of $729.17 million and reported a net profit loss of $10 million.
How big is Trevi Therapeutics, Inc.?
As of Jun 18, Trevi Therapeutics, Inc. has a market capitalization of 729.17 million, categorizing it as a Micro Cap company. As of Jun 24, net sales for the latest four quarters are 0.00 million, with a net profit of -47.34 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
